Statement: All Cohorts of the primary trial and the secondary trial receive their treatment via Subcutaneous administration.
Primary_evidence: INTERVENTION 1:    Initial Cohort   Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms   Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule INTERVENTION 2:    Escalation Cohort   Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms   Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule
Secondary_evidence: INTERVENTION 1:    Active Medicine Group   risedronate 35 mg weekly INTERVENTION 2:    Placebo Group   Received placebo medication once weekly